Skip to main navigation
Fulcrum Therapeutics logo
Menu Button

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact

News Releases

News Releases

Mar 10, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 09, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
Mar 06, 2023
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
Feb 24, 2023
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
Feb 10, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 08, 2023
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
Jan 17, 2023
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Jan 17, 2023
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
Jan 13, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 04, 2023
Fulcrum Therapeutics Provides Business Update and 2023 Outlook

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 11

Investor Tools

Print
Email Page
Email Alerts
IR Contact
Privacy Policy | EU Privacy Policy | Terms of use
Fulcrum TX
Social Media Guidelines

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact